NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Imatinib in Adult Patients With Metastatic Ocular Melanoma

NCT00421317

TerminatedPhase 2

Sponsor: Centre Oscar Lambret

Conditions: Melanoma

Interventions: Imatinib

Countries: France

The scope of the trial is to determinate the anti-tumoral activity of imatinib in metastatic ocular melanoma patients.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Metastatic ocular melanoma
* Age \> or = 18 years old
* Measurable metastases \> or = 10 mm according to RECIST criteria
* PS-WHO \< or = 1 or IK \> 70 percent
* Normal hepatic function
* PNN \> 1500/mm3, platelets \> or = 100 000/mm3
* Contraception
* Informed consent signed

Exclusion Criteria:

* Patient with two prior lines of systemic treatment (chemotherapy, immunotherapy or association)
* Other evolutive neoplasic disease
* Severe hepatic insufficiency
* Severe renal insufficiency
* Somatic or psychiatric co-morbidity incompatible with the protocol
* Leptomeningeal or cerebral metastatic dissemination
* Pregnant or lactating woman
* Other antitumoral treatment
* Patient participating to another clinical trial with an experimental drug
* Known hypersensitivity to Imatinib or one of its excipients
* Resecable single metastasis

Locations (12)

Caen, France
Clermont-Ferrand, France
Dijon, France
Lille, France
Lille, France
Lyon, France
Montpellier, France
Paris, France
Strasbourg, France
Strasbourg, France
Toulouse, France
Villejuif, France